Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

1,090 results
Display

How to predict treatment failure in frail patients with advanced epithelial ovarian cancer: strategies to personalize surgical effort

Fotopoulou C

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer

Park J, Eoh KJ, Nam EJ, Kim S, Kim SW, Kim YT, Lee JY

PURPOSE: We evaluated whether adding bevacizumab to current platinum-based chemotherapy could improve clinical outcomes without affecting safety. MATERIALS AND METHODS: We retrospectively reviewed medical records of patients with pathologically confirmed ovarian...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Germline PALB2, ATM variants in a patient with breast and ovarian cancer at risk for familial cancer syndrome: Is there a role for risk-reducing salpingo-oophorectomy?

Carbajal-Mamani SL, Markham MJ, Santolaya-Forgas J, Castagno J, Cardenas-Goicoechea J

A 50-year-old non-Hispanic white Caucasian female was diagnosed with breast cancer and was subsequently found to possess the tumorigenic ataxia telangiectasia mutated (ATM) and PALB2 variants but not the BRCA1...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Robotic-assisted interval cytoreductive surgery in ovarian cancer: a feasibility study

Carbajal-Mamani SL, Schweer D, Markham MJ, Esnakula A, Grajo JR, Castagno J, Cardenas-Goicoechea J

OBJECTIVE: The primary objective was to assess the feasibility of robotic-assisted interval cytoreductive surgery for achieving complete cytoreduction for patients with advanced-stage ovarian cancer. The secondary objective was to examine...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison between weekly versus 3-weekly paclitaxel in combination with carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer

Kim YN, Lee YJ, Lee JY, Nam EJ, Kim SW, Kim S, Kim YT

OBJECTIVE: To compare the efficacy and toxicity of dose-dense weekly paclitaxel and 3-weekly carboplatin (ddPC) as neoadjuvant chemotherapy (NAC) with the standard 3-weekly regimen. METHODS: A retrospective study of patients diagnosed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study

Park SJ, Kim J, Kim HS, Lee JW, Chang HK, Lee KH, Kim DY, Kim S, Chang SJ, Han SS, Park SY, Shim SH

OBJECTIVE: To evaluate the effectiveness and safety of the combination of pegylated liposomal doxorubicin with carboplatin (CD) compared with those of carboplatin and paclitaxel (CP) for platinum-sensitive recurrent ovarian, fallopian,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Tozzi classification of diaphragmatic surgery in patients with stage IIIC–IV ovarian cancer based on surgical findings and complexity

Tozzi R, Ferrari F, Nieuwstad , Campanile , Soleymani Majd H

OBJECTIVE: To introduce a systematic classification of diaphragmatic surgery in patients with ovarian cancer based on disease spread and surgical complexity. METHODS: For all consecutive patients who underwent diaphragmatic surgery during...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy and safety of neoadjuvant chemotherapy versus primary debulking surgery in patients with ovarian cancer: a meta-analysis

Lv X, Cui S, Zhang X, Ren C

OBJECTIVE: Neoadjuvant chemotherapy (NACT) for the treatment of epithelial ovarian cancer (EOC) has remained controversial. This meta-analysis was performed to systematically assess the efficacy and safety of NACT versus primary...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies

Lee A, Moon BI, Kim TH

Hereditary breast cancer is known for its strong tendency of inheritance. Most hereditary breast cancers are related to BRCA1/BRCA2 pathogenic variants. The lifelong risk of breast cancer in pathogenic BRCA1...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery

Liu YL, Filippova OT, Zhou Q, Iasonos A, Chi DS, Zivanovic O, Sonoda Y, Gardner GJ, Broach VA, O'Cearbhaill RE, Konner JA, Aghajanian C, Long Roche K, Tew WP

OBJECTIVE: Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) confers similar outcomes as primary debulking surgery and chemotherapy. Little is known about patients who receive NACT but do not...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Factors associated with surgical morbidity of primary debulking in epithelial ovarian cancer

Günakan E, Tohma YA, Tunç M, Akıllı H, Şahin H, Ayhan A

OBJECTIVE: Epithelial ovarian cancer (EOC) requires an aggressive surgical approach. The important part of literature on ovarian cancer surgery emphasize residual tumor and survival analyses. Morbidity issue keeps in background....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Potential predictors for chemotherapeutic response and prognosis in epithelial ovarian, fallopian tube and primary peritoneal cancer patients treated with platinum-based chemotherapy

Jeerakornpassawat D, Suprasert

OBJECTIVE: This study aimed to investigate the potential predictive factors for platinum resistance and poor prognosis in epithelial ovarian, fallopian tube, and primary peritoneal cancer treated with platinum-based chemotherapy. METHODS: Medical...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Contralateral Breast Cancer and Ipsilateral Breast Tumor Recurrence in BRCA1/2 Carriers and Non-Carriers at High-Risk of Hereditary Breast Cancer

Yoon KH, Chae S, Kang E, Shin HC, Kim JH, Kim IA, Park SY, Kim SW, Kim EK

PURPOSE: We evaluated the risk of contralateral breast cancer (CBC) and ipsilateral breast tumor recurrence (IBTR) and investigated the predictive factors for CBC and IBTR in breast cancer patients with...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Knowledge and Anxiety Related to Hereditary Ovarian Cancer in Serous Ovarian Cancer Patients

Lee SH, Lee H, Lim MC, Kim S

PURPOSE: The awareness of hereditary breast and ovarian cancer (HBOC) and BRCA testing is increasing in Korea. Compared to the sizable research on HBOC knowledge among breast cancer women, studies...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
MiR-338-3p Enhances Ovarian Cancer Cell Sensitivity to Cisplatin by Downregulating WNT2B

Niu Q, Liu Z, Gao J, Wang Q

PURPOSE: Chemoresistance is a concern in ovarian cancer patients, in whom survival remains. MicroRNA, a novel class of small RNAs, have frequently been found to be dysregulated in human malignancies...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Incidental Ovarian Lesions

Kang S, Park JJ, Park SY

Incidental ovarian lesions are diagnostic challenges owing to their wide disease spectrum, ranging from normal findings to malignant ovarian tumors. There are several physiologic ovarian lesions that may not require...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prevalence and oncologic outcomes of BRCA1/2 mutation and variant of unknown significance in epithelial ovarian carcinoma patients in Korea

Seo JH, Jeong SY, Kim MS, Kang JH, Paik ES, Lee YY, Kim TJ, Lee JW, Kim BG, Bae DS, Choi CH

OBJECTIVE: BRCA mutational status is important in the management of ovarian cancer, but there is a lack of evidence supporting genetic testing in Asian populations. This study was performed to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Which patients benefit from secondary cytoreductive surgery in recurrent ovarian cancer?

Zang R, Zhu J

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Neoadjuvant chemotherapy for epithelial ovarian cancer in Japan: a JSGO-JSOG joint study

Machida H, Matsuo K, Enomoto T, Mikami M

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D

Lee JY, Kim JW, Lim MC, Kim S, Kim HS, Choi CH, Yi JY, Park SY, Kim BG, on behalf of KGOG investigators

BACKGROUND: A single-arm phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in the treatment of advanced-stage ovarian cancer has begun in Korea. We hypothesized that adding durvalumab (anti-programmed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr